JenaValve Trilogy successfully implanted for the first time in Asia at Queen Elizabeth Hospital, Hong Kong.
Enrollment commenced for the TaurusTrio™ multi-center clinical trial in China for aortic valve regurgitation treatment.
MonarQ TTVR System achieved successful first-in-human implantation in the U.S.
HighLife multi-center clinical trial investigator coordination meeting held at the Chengdu Valve Conference.
Spearheaded the establishment of the Suzhou Interventional Medical Technology Innovation Consortium.
DCwire™ microguidewire and NRCoil™ detachable coils approved for market launch in the neurointerventional field.
Global headquarters officially inaugurated.
